FOLH1 and prostate cancer: The discovery of new developed radioiodinated, 123I-MIP-1072 and 123I-MIP-1095 (Figure 3) PSMA ligands based on urea scaffold have been reported in the literature.25,51-53 Despite the encouraging earlier clinical results, it appears that further attempts to optimize the efficacy and reduce the side effects of these radioiodinated ligands are warranted.30 As a result, the development of 123I-MIP-1072 and 123I-MIP-1095 has initiated the development of other PSMA-based urea binding motif radiopharmaceuticals eligible for prostate cancer.23